141 related articles for article (PubMed ID: 2338132)
1. Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo.
Clibon U; Bonewald L; Caro J; Roodman GD
Exp Hematol; 1990 Jun; 18(5):438-41. PubMed ID: 2338132
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of erythroid suppression in the anemia of chronic disease.
Roodman GD
Blood Cells; 1987; 13(1-2):171-84. PubMed ID: 2822178
[TBL] [Abstract][Full Text] [Related]
3. Improvement of erythroid toxicity by lentinan and erythropoietin in mice treated with chemotherapeutic agents.
Takatsuki F; Miyasaka Y; Kikuchi T; Suzuki M; Hamuro J
Exp Hematol; 1996 Feb; 24(3):416-22. PubMed ID: 8599970
[TBL] [Abstract][Full Text] [Related]
4. In vivo suppression of erythropoiesis by tumor necrosis factor-alpha (TNF-alpha): reversal with exogenous erythropoietin (EPO).
Johnson CS; Cook CA; Furmanski P
Exp Hematol; 1990 Feb; 18(2):109-13. PubMed ID: 2303102
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice.
Otsuki T; Nagakura S; Wang J; Bloom M; Grompe M; Liu JM
J Cell Physiol; 1999 Apr; 179(1):79-86. PubMed ID: 10082135
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor alpha and the anemia of chronic disease: effects of chronic exposure to TNF on erythropoiesis in vivo.
Roodman GD; Johnson RA; Clibon U
Adv Exp Med Biol; 1989; 271():185-96. PubMed ID: 2486284
[TBL] [Abstract][Full Text] [Related]
7. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
Wisniewski D; Strife A; Atzpodien J; Clarkson BD
Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
[TBL] [Abstract][Full Text] [Related]
8. The in vivo effects of recombinant human erythropoietin on cisdiamminodichloroplatinum-induced anemia in golden Syrian hamsters.
Gebbia V; Palmeri S; Valenza R; Rausa L; Citarrella P
In Vivo; 1991; 5(2):149-52. PubMed ID: 1768784
[TBL] [Abstract][Full Text] [Related]
9. The effect of recombinant human erythropoietin on circulating hematopoietic progenitor cells in anemic premature infants.
Meister B; Maurer H; Simma B; Kern H; Ulmer H; Hittmair A; Fink FM
Stem Cells; 1997; 15(5):359-63. PubMed ID: 9323798
[TBL] [Abstract][Full Text] [Related]
10. Erythroid progenitors in tumor-bearing mice: erythroid inhibitory factors produced by adenocarcinoma-755.
Aoki I; Toyama K; Abe N; Yamamoto M; Ishikawa K
Exp Hematol; 1991 Sep; 19(8):789-96. PubMed ID: 1868894
[TBL] [Abstract][Full Text] [Related]
11. Protection of zidovudine-induced toxicity against murine erythroid progenitor cells by vitamin E.
Gogu SR; Lertora JJ; George WJ; Hyslop NE; Agrawal KC
Exp Hematol; 1991 Aug; 19(7):649-52. PubMed ID: 1893952
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha and hematopoietic progenitors: effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K562, HL60, and HEL cells.
Roodman GD; Bird A; Hutzler D; Montgomery W
Exp Hematol; 1987 Oct; 15(9):928-35. PubMed ID: 2820776
[TBL] [Abstract][Full Text] [Related]
13. Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alpha.
Tsopra OA; Ziros PG; Lagadinou ED; Symeonidis A; Kouraklis-Symeonidis A; Thanopoulou E; Angelopoulou MK; Vassilakopoulos TP; Pangalis GA; Zoumbos NC
Acta Haematol; 2009; 121(4):187-95. PubMed ID: 19468203
[TBL] [Abstract][Full Text] [Related]
14. Optimal erythroid cell production during erythropoietin treatment of mice occurs by exploiting the splenic microenvironment.
Nijhof W; Goris H; Dontje B; Dresz J; Loeffler M
Exp Hematol; 1993 Apr; 21(4):496-501. PubMed ID: 8462658
[TBL] [Abstract][Full Text] [Related]
15. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
[TBL] [Abstract][Full Text] [Related]
16. Stimulatory effect of human insulin on erythroid progenitors (CFU-E and BFU-E) in human CD34+ separated bone marrow cells and the relationship between insulin and erythropoietin.
Aoki I; Taniyama M; Toyama K; Homori M; Ishikawa K
Stem Cells; 1994 May; 12(3):329-38. PubMed ID: 7521243
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo.
Uy HL; Mundy GR; Boyce BF; Story BM; Dunstan CR; Yin JJ; Roodman GD; Guise TA
Cancer Res; 1997 Aug; 57(15):3194-9. PubMed ID: 9242449
[TBL] [Abstract][Full Text] [Related]
19. Interferon-gamma exerts its negative regulatory effect primarily on the earliest stages of murine erythroid progenitor cell development.
Wang CQ; Udupa KB; Lipschitz DA
J Cell Physiol; 1995 Jan; 162(1):134-8. PubMed ID: 7814445
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
